Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avocadyne is a **polyhydroxylated fatty alcohol** (C₁₇H₃₂O₃) of natural origin, primarily extracted from avocado (*Persea americana*). Structurally, it is distinguished as a 17-carbon terminally unsaturated acetogenin, featuring a triple bond at the terminal carbon and hydroxyl groups at carbons 1, 2, and 4. Avocadyne exhibits **potent bioactivity through direct inhibition of very long chain acyl-CoA dehydrogenase (VLCAD)**, a key mitochondrial enzyme in the **fatty acid oxidation (FAO) pathway**. This action disrupts energy generation in **acute myeloid leukemia (AML) cells**, leading to selective induction of apoptosis in malignant, but not normal, hematopoietic cells. Preclinical evidence also supports roles in enhancing **insulin sensitivity** and **improving glucose tolerance**, with potential application in the management of diabetes. Avocadyne has shown **antiviral properties** in preclinical studies. Its presence is documented both in avocado pulp and seeds, and it is being explored as a candidate for pharmaceutical and dietary supplement use for AML and metabolic diseases[1][2][3][4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avocadyne.